Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 8/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6415642 | 0.93 | CCR5 (0.46) | ROCK2ROCK1CCR5CTSBCTSS | |
| SCHEMBL6409501 | 0.91 | HCRTR2 (0.43) | ROCK2ROCK1CCR5CTSBCTSS | |
| SCHEMBL6409016 | 0.91 | HCRTR2 (0.43) | ROCK2ROCK1CCR5CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6410988 | 0.90 | HCRTR2 (0.42) | ROCK2ROCK1CCR5CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6410911 | 0.89 | UTS2R (0.46) | CCR5CTSBCTSSCTSKUTS2R | |
| SCHEMBL6409300 | 0.89 | CCR5 (0.44) | ROCK2ROCK1CCR5CTSBCTSS | |
| SCHEMBL6409295 | 0.89 | CCR5 (0.44) | ROCK2ROCK1CCR5CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6432231 | 0.89 | CCR5 (0.44) | CCR5CCR2CTSBCTSSCTSK | |
| SCHEMBL5306993 | 0.89 | CCR5 (0.43) | ROCK2ROCK1CCR5CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6415352 | 0.89 | CCR5 (0.43) | ROCK2ROCK1CCR5CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | ROCK2 1735/4885ROCK1 1002/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.